<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_TokyoTech_Testing_Page skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:TokyoTech/Testing Page</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><P>&lt;!DOCTYPE html&gt;<TITLE>Coli Sapiens</TITLE><NAV class="w3-sidebar w3-red w3-collapse w3-top w3-large w3-padding" style="z-index:3;width:300px;font-weight:bold;" id="mySidebar"><A href="javascript:void(0)" onclick="w3_close()" class="w3-button w3-hide-large w3-display-topleft" style="width:100%;font-size:20px">Close Menu</A></NAV></P><DIV style="padding-top: 15px; padding-left: 25px;"><DIV id="contents" style="z-index: 10"><UL class="click_menu_checkbox vertm_down"><LI style="margin-bottom: 10px; border: 5px double #fff; border-radius: 10px;"><LABEL for="vmcb-a"><A href="https://2017.igem.org/Team:TokyoTech">Home</A></LABEL></LI><LI style="margin-bottom: 10px; border: 5px double #fff; border-radius: 10px"><LABEL for="vmcb-b"><A href="https://2017.igem.org/Team:TokyoTech/Medal">Achievements</A></LABEL></LI><LI style="margin-bottom: 10px; border: 5px double #fff; border-radius: 10px"><LABEL for="vmcb-c"><A>Project</A></LABEL></LI><LI style="text-align: center;"><A href="https://2017.igem.org/Team:TokyoTech/Description" class="w3-bar-item w3-button w3-hover-white">Description</A></LI><LI style="text-align: center;"><A href="https://2017.igem.org/Team:TokyoTech/Project/Basic_Parts" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Basic Parts</A></LI><LI style="text-align: center;"><A href="https://2017.igem.org/Team:TokyoTech/Project/Composite_Parts" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Composite Parts</A></LI></UL><LI style="margin-bottom: 10px; border: 5px double #fff; border-radius: 10px"><LABEL for="vmcb-d"><A>Experiment</A></LABEL></LI><LI style="padding-bottom: 10px; padding-top: 10px"><LABEL for="vmcb-d1"><A style="text-align: center;">Bacteria to Human Cells ▼</A></LABEL></LI><LI style="text-align: center;"><A href="https://2017.igem.org/Team:TokyoTech/Experiment/TraI_Assay" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">TraI Assay</A></LI><LI style="text-align: center;"><A href="https://2017.igem.org/Team:TokyoTech/Experiment/TraI_Improvement" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">TraI  Impovement</A></LI><LI style="text-align: center;"><A href="https://2017.igem.org/Team:TokyoTech/Experiment/TraR_Reporter_Assay" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">TraR Reporter  Assay</A></LI><LI style="text-align: center;"><A href="https://2017.igem.org/Team:TokyoTech/Experiment/Transcriptome_Analysis" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Transcriptome  Analysis</A></LI><LI style="text-align: center;"><A href="https://2017.igem.org/Team:TokyoTech/Experiment/C8_Toxicity" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">C8 Toxicity  Assay</A></LI><LI style="text-align: center;"><A href="https://2017.igem.org/Team:TokyoTech/Experiment/Chimeric_Transcription_Factor" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Chimeric  Transcription  Factor</A></LI><LI style="padding-bottom: 10px"><LABEL for="vmcb-d2"><A style="text-align: center;">Human Cells to Bacteria ▼</A></LABEL></LI><LI><A href="https://2017.igem.org/Team:TokyoTech/Experiment/AHK4_Assay" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">AHK4 Assay</A></LI><LI style="padding-bottom: 10px"><LABEL for="vmcb-d3"><A style="text-align: center;">InterLab</A></LABEL></LI><LI style="margin-bottom: 10px; text-align: center; border: 5px double #fff; border-radius: 10px"><LABEL for="vmcb-e"><A href="https://2017.igem.org/Team:TokyoTech/Model">Modelling</A></LABEL></LI><LI style="margin-bottom: 10px; text-align: center; border: 5px double #fff; border-radius: 10px"><LABEL for="vmcb-f"><A>Human Practices</A></LABEL></LI><LI style="text-align: center;"><A href="https://2017.igem.org/Team:TokyoTech/HP" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Overview</A></LI><LI style="text-align: center;"><A href="https://2017.igem.org/Team:TokyoTech/HP/Silver" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Silver</A></LI><LI style="text-align: center;"><A href="https://2017.igem.org/Team:TokyoTech/HP/Gold_Integrated" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Integrated  Human Practice</A></LI><LI style="text-align: center;"><A href="https://2017.igem.org/Team:TokyoTech/Demonstrate" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Demonstrate</A></LI><LI style="text-align: center;"><A href="https://2017.igem.org/Team:TokyoTech/Collaborations" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Collaborations</A></LI><LI style="margin-bottom: 10px; text-align: center; border: 5px double #fff; border-radius: 10px"><LABEL for="vmcb-g"><A>About us</A></LABEL></LI><LI style="text-align: center;"><A href="https://2017.igem.org/Team:TokyoTech/Team" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Team</A></LI><LI style="text-align: center;"><A href="https://2017.igem.org/Team:TokyoTech/Attributions" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Attributions</A></LI><LI style="text-align: center;"><A href="https://2017.igem.org/Team:TokyoTech/Sponsors" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Sponsors</A></LI></DIV></DIV><HEADER class="w3-container w3-top w3-hide-large w3-red w3-xlarge w3-padding"><SPAN style="padding-top: 5px">iGEM Tokyo Tech</SPAN></HEADER><DIV class="w3-main" style="margin-left:340px;margin-right:40px"><DIV class="w3-container" id="overview" style="margin-top:20px"><H1 class="w3-xxxlarge w3-text-red" style="padding-bottom: 10px;padding-top: 10px"><B>Overview</B></H1><H2> proliferation in them. So, we try to establish a new living system that h</H2><H3> proliferation in them. So, we try to establish a new living system that h</H3><H4> proliferation in them. So, we try to establish a new living system that h</H4><P style="font-family: Poppins;font-size: 16px">Gene therapy has been expected in cancer therapy for years. An interesting therapy for cancer using anaerobic bacteria as a carrier has been developed, but after the anaerobic cancer region is diminished, the bacteria cannot stay there anymore. If anti-cancer bacteria can stay in affected area, they promptly respond to cancer recurrence. Co-existence of bacteria and host cells should be quite difficult in our body or human cell culture systems, because bacteria grow so fast. It is important to control bacterial proliferation in them. So, we try to establish a new living system that human cells control the population of bacteria by engineering the both cells by creating two signaling pathways of 1) Bacteria-Mammals and 2) Bacteria-Plants. We expect that this system will lead to a new experimental approach and a new medical therapy. Moreover, we imagine about &quot;A boundary between cellular groups and living organisms&quot; with general public.
    </P></DIV><DIV class="w3-container" id="project" style="margin-top:20px"><H1 class="w3-xxxlarge w3-text-red" style="padding-bottom: 10px;padding-top: 10px"><B>Project   </B><BUTTON class="w3-button w3-red w3-padding-large w3-hover-black" style="font-size: 25px"><A href="https://2017.igem.org/Team:TokyoTech/Project">Read More</A></BUTTON></H1><P style="font-family: Poppins;font-size: 16px">Gene therapy has been expected in cancer therapy for years. An interesting therapy for cancer using anaerobic bacteria as a carrier has been developed, but after the anaerobic cancer region is diminished, the bacteria cannot stay there anymore. If anti-cancer bacteria can stay in affected area, they promptly respond to cancer recurrence. Co-existence of bacteria and host cells should be quite difficult in our body or human cell culture systems, because bacteria grow so fast. It is important to control bacterial proliferation in them. So, we try to establish a new living system that human cells control the population of bacteria by engineering the both cells by creating two signaling pathways of 1) Bacteria-Mammals and 2) Bacteria-Plants. We expect that this system will lead to a new experimental approach and a new medical therapy. Moreover, we imagine about &quot;A boundary between cellular groups and living organisms&quot; with general public.
    </P></DIV><DIV class="w3-container" id="modeling" style="margin-top:20px"><H1 class="w3-xxxlarge w3-text-red" style="padding-bottom: 10px;padding-top: 10px"><B>Modeling   </B><BUTTON class="w3-button w3-red w3-padding-large w3-hover-black" style="font-size: 25px"><A href="https://2017.igem.org/Team:TokyoTech/Modeling">Read More</A></BUTTON></H1><P style="font-family: Poppins;font-size: 16px">Gene therapy has been expected in cancer therapy for years. An interesting therapy for cancer using anaerobic bacteria as a carrier has been developed, but after the anaerobic cancer region is diminished, the bacteria cannot stay there anymore. If anti-cancer bacteria can stay in affected area, they promptly respond to cancer recurrence. Co-existence of bacteria and host cells should be quite difficult in our body or human cell culture systems, because bacteria grow so fast. It is important to control bacterial proliferation in them. So, we try to establish a new living system that human cells control the population of bacteria by engineering the both cells by creating two signaling pathways of 1) Bacteria-Mammals and 2) Bacteria-Plants. We expect that this system will lead to a new experimental approach and a new medical therapy. Moreover, we imagine about &quot;A boundary between cellular groups and living organisms&quot; with general public.
    </P></DIV><DIV class="w3-container" id="hp" style="margin-top:20px"><H1 class="w3-xxxlarge w3-text-red" style="padding-bottom: 10px;padding-top: 10px"><B>Human Practices   </B><BUTTON class="w3-button w3-red w3-padding-large w3-hover-black" style="font-size: 25px"><A href="https://2017.igem.org/Team:TokyoTech/Human_Practices">Read More</A></BUTTON></H1><P style="font-family: Poppins;font-size: 16px">Gene therapy has been expected in cancer therapy for years. An interesting therapy for cancer using anaerobic bacteria as a carrier has been developed, but after the anaerobic cancer region is diminished, the bacteria cannot stay there anymore. If anti-cancer bacteria can stay in affected area, they promptly respond to cancer recurrence. Co-existence of bacteria and host cells should be quite difficult in our body or human cell culture systems, because bacteria grow so fast. It is important to control bacterial proliferation in them. So, we try to establish a new living system that human cells control the population of bacteria by engineering the both cells by creating two signaling pathways of 1) Bacteria-Mammals and 2) Bacteria-Plants. We expect that this system will lead to a new experimental approach and a new medical therapy. Moreover, we imagine about &quot;A boundary between cellular groups and living organisms&quot; with general public.
    </P></DIV><DIV class="w3-container" id="notebook" style="margin-top:20px"><H1 class="w3-xxxlarge w3-text-red" style="padding-bottom: 10px;padding-top: 10px"><B>Notebook   </B><BUTTON class="w3-button w3-red w3-padding-large w3-hover-black" style="font-size: 25px"><A href="https://2017.igem.org/Team:TokyoTech/Notebook">Read More</A></BUTTON></H1><P style="font-family: Poppins;font-size: 16px">Gene therapy has been expected in cancer therapy for years. An interesting therapy for cancer using anaerobic bacteria as a carrier has been developed, but after the anaerobic cancer region is diminished, the bacteria cannot stay there anymore. If anti-cancer bacteria can stay in affected area, they promptly respond to cancer recurrence. Co-existence of bacteria and host cells should be quite difficult in our body or human cell culture systems, because bacteria grow so fast. It is important to control bacterial proliferation in them. So, we try to establish a new living system that human cells control the population of bacteria by engineering the both cells by creating two signaling pathways of 1) Bacteria-Mammals and 2) Bacteria-Plants. We expect that this system will lead to a new experimental approach and a new medical therapy. Moreover, we imagine about &quot;A boundary between cellular groups and living organisms&quot; with general public.
    </P></DIV><DIV class="w3-container" id="team" style="margin-top:20px"><H1 class="w3-xxxlarge w3-text-red" style="padding-bottom: 10px;padding-top: 10px"><B>Team   </B><BUTTON class="w3-button w3-red w3-padding-large w3-hover-black" style="font-size: 25px"><A href="https://2017.igem.org/Team:TokyoTech/Team">Read More</A></BUTTON></H1><P style="font-family: Poppins;font-size: 16px">Gene therapy has been expected in cancer therapy for years. An interesting therapy for cancer using anaerobic bacteria as a carrier has been developed, but after the anaerobic cancer region is diminished, the bacteria cannot stay there anymore. If anti-cancer bacteria can stay in affected area, they promptly respond to cancer recurrence. Co-existence of bacteria and host cells should be quite difficult in our body or human cell culture systems, because bacteria grow so fast. It is important to control bacterial proliferation in them. So, we try to establish a new living system that human cells control the population of bacteria by engineering the both cells by creating two signaling pathways of 1) Bacteria-Mammals and 2) Bacteria-Plants. We expect that this system will lead to a new experimental approach and a new medical therapy. Moreover, we imagine about &quot;A boundary between cellular groups and living organisms&quot; with general public.
    </P></DIV><DIV class="w3-container" id="sponsers" style="margin-top:75px;"><H1 class="w3-xxxlarge w3-text-red" style="padding-top: 10px;padding-bottom: 10px"><B>Sponsers</B></H1></DIV><DIV class="w3-row-padding"><DIV class="w3-col m4 w3-margin-bottom"><DIV class="w3-light-grey"><DIV class="w3-container"><H3>JASSO</H3></DIV></DIV></DIV><DIV class="w3-col m4 w3-margin-bottom"><DIV class="w3-light-grey"><DIV class="w3-container"><H3>Kuramae Kougyoukai</H3></DIV></DIV></DIV><DIV class="w3-col m4 w3-margin-bottom"><DIV class="w3-light-grey"><DIV class="w3-container"><H3>IDT</H3></DIV></DIV></DIV></DIV></DIV><DIV class="w3-light-grey w3-container w3-padding-32" style="margin-top:75px;padding-right:58px"><P class="w3-right">Hajime Fujita:  <A href="96haji.me" title="W3.CSS" target="_blank" class="w3-hover-opacity">All Rights Reserved</A></P></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>